FDA Approves......
FDA Approves......
Lumateperone (Caplyta) has been approved as an adjunctive (add-on) therapy for adults with Major Depressive Disorder (MDD) whose symptoms persist despite treatment with an antidepressant.
It expands lumateperone’s indication beyond its prior uses (for example in schizophrenia and bipolar depression).
The approval was supported by two Phase 3, global, double-blind, placebo-controlled trials in adults with MDD on an antidepressant but remaining symptomatic.
References:
Steinzor, P. (2025, November 6). FDA approves Lumateperone as Add-On therapy for major depressive Disorder. AJMC - Managed Care News, Research, and Expert Insights. https://www.ajmc.com/view/fda-approves-lumateperone-as-add-on-therapy-for-major-depressive-disorder
Bipolar Disorder
Bipolar disorder is a mental health condition that causes a person’s mood to swing between high and low states. During the high, called mania or hypomania, a person may feel very happy, full of energy, talk a lot, or make quick decisions without thinking. During the low, called depression, they may feel very sad, tired, or lose interest in things they normally enjoy. These mood changes can affect sleep, energy, and daily life. With the right treatment, such as medication, therapy, and support, people with bipolar disorder can manage their moods and live healthy, balanced lives.
References:
Oliva, V., Fico, G., De Prisco, M., Gonda, X., Rosa, A. R., & Vieta, E. (2024). Bipolar disorders: an update on critical aspects. The Lancet regional health. Europe, 48, 101135. https://doi.org/10.1016/j.lanepe.2024.101135
Evolution of Telehealth in Ambulatory Psychiatry: A One Year Perspective
This article examines how an academic outpatient psychiatry clinic transitioned from in-person care to telehealth during the first year of the COVID-19 pandemic. Beginning in March 2020, nearly all visits were rapidly converted to virtual formats (video or phone) to maintain care continuity while reducing infection risk.
Over the course of one year:
Total visit volume slightly increased compared to pre-pandemic levels.
No-show and cancellation rates decreased by more than 10%.
Around 65% of visits were conducted via video, the rest by telephone.
Patient satisfaction remained high—over 90% felt their needs were met.
The authors highlight telehealth’s success in ensuring uninterrupted psychiatric care and expanding access. Benefits included improved attendance, convenience, and continuity for existing patients.